問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2020-08-01 - 2024-11-29

Phase I

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    GNX102

Participate Sites
2Sites

Recruiting2Sites

2009-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-04-01 - 2010-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-11-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-07-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-05-01 - 2014-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-08-01 - 2014-06-30

Phase III

A phase 3 study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin(P/R), Intolerant or Ineligible to P/R Subjects and Treatment –Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    Asunaprevir (BMS-650032)、Daclatasvir (BMS-790052)

Participate Sites
8Sites

Terminated8Sites

2012-10-01 - 2015-04-30

Phase II

An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-650032 Asunaprevir / BMS-790052 Daclatasvir

Participate Sites
8Sites

Terminated8Sites

2013-02-01 - 2016-12-31

Phase III

A Phase 3 Randomized, Double Blind, Regional Multi-National Evaluation of Daclatasvir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotypes 1 and 4

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-790052

Participate Sites
10Sites

Terminated10Sites

1 176 177 178 179 180 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB